Coronavirus channel feed

UK cost watch­dog drafts guid­ance against 5 Covid treat­ments and J&J de­pres­sion med

3 years ago
Pharma
FDA+

Biden looks for $9B+ in new Covid funds as Sen­ate pass­es res­o­lu­tion to end emer­gency de­c­la­ra­tion

3 years ago
FDA+

Mod­er­na touts 'su­pe­ri­or' an­ti­body lev­els against Omi­cron for au­tho­rized Covid-19 bi­va­lent boost­er

3 years ago
R&D
Pharma

EMA signs off on Sanofi and GSK's BAR­DA-fund­ed Covid boost­er shot

3 years ago

In wan­ing Covid mar­ket, MiNK un­veils da­ta on nat­ur­al killer T cell ther­a­py for ARDS, pend­ing con­tract with DARPA

3 years ago
R&D

No­vavax tem­pers its rev­enue ex­pec­ta­tions as it un­veils PhI­II da­ta for bi­va­lent boost­er

3 years ago
R&D
Pharma

FDA ten­ta­tive­ly hints at EUA, with a tri­al re­quire­ment, for Veru's new Covid drug ahead of ad­comm

3 years ago
FDA+

Scoop: Call­ing off an IPO, a can­cer and Covid-19 vac­cine mak­er rais­es a Se­ries C

3 years ago
Financing
Startups

Rigel churns out an­oth­er late-stage clin­i­cal fail­ure — this time in Covid-19

3 years ago
R&D

HHS re­news 'call to ac­tion' with Covid boost­er ad spots

3 years ago
Pharma
Marketing

Covid-19 con­tin­ues to be­fud­dle Big Phar­ma as Ab­b­Vie ax­es PhI of an oral drug

3 years ago
R&D

Covid-19 spurred a his­toric vac­cine R&D ef­fort. What does it mean for fu­ture pan­demics?

3 years ago
R&D
In Focus

NIH to study Pfiz­er's Paxlovid in long Covid as de­mand — and in­fec­tions — con­tin­ue to fall

3 years ago

Emer­gency clin­i­cal re­search: Biden's OSTP wants to set­tle 'key terms' in ad­vance of tri­als

3 years ago

Re­cent use of Pfiz­er's Covid pill de­clines sharply com­pared to this sum­mer

3 years ago

As gov­ern­ment fund­ing dries up, Pfiz­er ex­pects to charge pri­vate pay­ers $110+ for Covid-19 vac­cine

3 years ago
Pharma

Covid-19 roundup: Mod­er­na rewrites agree­ment with Gavi; Bavar­i­an Nordic touts PhII boost­er re­sults

3 years ago

FDA au­tho­rizes ado­les­cent use of Omi­cron-spe­cif­ic boost­ers

3 years ago
Pharma

Pfiz­er ex­ec de­nies vac­cine ne­go­ti­a­tions via text mes­sage in grilling be­fore Eu­ro­pean Par­lia­ment

3 years ago
Deals
Pharma

No speedy nasal roll­out for Ox­ford/As­traZeneca’s Covid-19 jab af­ter PhI flop

3 years ago
R&D
Pharma

Amid al­ready plung­ing use of Mer­ck’s Covid-19 an­tivi­ral Lagevrio, preprint gives look in­to re­al world per­for­mance

3 years ago
R&D

FDA re­jects Eiger's emer­gency use re­quest for re­pur­posed Covid-19 treat­ment

3 years ago
FDA+

Af­ter Covid set­back, Val­ne­va lines up $100M for Pfiz­er-al­lied Ly­me dis­ease PhI­II

3 years ago
Financing
Pharma

In post-Covid life, Vir looks to stomp out in­fluen­za in up to $1B BAR­DA con­tract that boosts GSK-al­lied mAb

3 years ago
Deals
First page Previous page 3456789 Next page Last page
A service from the Financial Times